Efficacy results of node-negative HER2-amplified breast cancer subset from BCIRG 006 study: A phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC-T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC-TH) with docetaxel, carboplatin, and trastuzumab (TCH).
V. Valero
No relevant relationships to disclose
D. J. Slamon
No relevant relationships to disclose
W. Eiermann
No relevant relationships to disclose
N. J. Robert
Consultant or Advisory Role - Pfizer; Roche; Sanofi
Honoraria - Roche; Sanofi
Research Funding - Pfizer
T. Pienkowski
No relevant relationships to disclose
M. Martin
No relevant relationships to disclose
J. R. Mackey
Honoraria - Roche; Sanofi
M. A. Lindsay
No relevant relationships to disclose
V. Bee-Munteanu
No relevant relationships to disclose
M. F. Press
No relevant relationships to disclose
G. Sauter
No relevant relationships to disclose
J. Crown
Consultant or Advisory Role - Roche; Sanofi
Honoraria - Roche; Sanofi
Research Funding - Roche; Sanofi